Tags

Type your tag names separated by a space and hit enter

SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.
Ophthalmologica 2017; 238(4):205-216O

Abstract

OBJECTIVE

To determine whether intraocular treatment with vascular endothelial growth factor (VEGF) inhibitors change systemic endothelial function (EF) in patients with neovascular age-related macular degeneration (AMD).

METHODS

In this prospective, randomized, 2-center, double-masked controlled interventional trial, patients with neovascular and dry AMD were enrolled. Eligible neovascular AMD patients received 2 intravitreal loading doses of either ranibizumab 0.5 mg or bevacizumab 1.25 mg at 4-week intervals and were subsequently followed every 4 weeks and treated according to a pro re nata regime for up to 1 year. Patients with dry AMD served as controls. The primary endpoint was the change in EF assessed by flow-mediated dilatation (FMD) after 2 months of treatment with VEGF inhibitors in patients with AMD compared to patients with dry AMD. FMD was assessed with B-mode high-resolution ultrasonography of the left brachial artery.

RESULTS

24 patients with neovascular AMD and 26 patients with dry ADM were included in the trial. Treatment with VEGF inhibitors did not significantly change FMD (from 4.7 ± 2.4 to 3.9 ± 1.9% after 8 weeks, p = 0.07, and to 5.1 ± 2.0% after 1 year; p = 0.93 vs. baseline, respectively).

CONCLUSIONS

EF did not significantly differ between patients with neovascular AMD treated with intravitreal VEGF inhibition and patients with dry AMD.

Authors+Show Affiliations

Department of Ophthalmology, City Hospital Triemli Zurich, Zurich, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

28866675

Citation

Enseleit, Frank, et al. "SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration." Ophthalmologica. Journal International D'ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, vol. 238, no. 4, 2017, pp. 205-216.
Enseleit F, Michels S, Sudano I, et al. SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. Ophthalmologica. 2017;238(4):205-216.
Enseleit, F., Michels, S., Sudano, I., Stahel, M., Zweifel, S., Schlager, O., ... Ruschitzka, F. (2017). SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. Ophthalmologica. Journal International D'ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 238(4), pp. 205-216. doi:10.1159/000478665.
Enseleit F, et al. SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. Ophthalmologica. 2017;238(4):205-216. PubMed PMID: 28866675.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. AU - Enseleit,Frank, AU - Michels,Stephan, AU - Sudano,Isabella, AU - Stahel,Marc, AU - Zweifel,Sandrine, AU - Schlager,Oliver, AU - Becker,Matthias, AU - Winnik,Stephan, AU - Nägele,Matthias, AU - Flammer,Andreas J, AU - Neidhart,Michel, AU - Graf,Nicole, AU - Matter,Christian M, AU - Seifert,Burkhardt, AU - Lüscher,Thomas F, AU - Ruschitzka,Frank, Y1 - 2017/09/02/ PY - 2016/11/23/received PY - 2017/06/12/accepted PY - 2017/9/4/pubmed PY - 2017/11/29/medline PY - 2017/9/4/entrez KW - Age-related macular degeneration KW - Bevacizumab KW - Clinical trial KW - Endothelial function KW - Ranibizumab KW - Vascular endothelial growth factor SP - 205 EP - 216 JF - Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde JO - Ophthalmologica VL - 238 IS - 4 N2 - OBJECTIVE: To determine whether intraocular treatment with vascular endothelial growth factor (VEGF) inhibitors change systemic endothelial function (EF) in patients with neovascular age-related macular degeneration (AMD). METHODS: In this prospective, randomized, 2-center, double-masked controlled interventional trial, patients with neovascular and dry AMD were enrolled. Eligible neovascular AMD patients received 2 intravitreal loading doses of either ranibizumab 0.5 mg or bevacizumab 1.25 mg at 4-week intervals and were subsequently followed every 4 weeks and treated according to a pro re nata regime for up to 1 year. Patients with dry AMD served as controls. The primary endpoint was the change in EF assessed by flow-mediated dilatation (FMD) after 2 months of treatment with VEGF inhibitors in patients with AMD compared to patients with dry AMD. FMD was assessed with B-mode high-resolution ultrasonography of the left brachial artery. RESULTS: 24 patients with neovascular AMD and 26 patients with dry ADM were included in the trial. Treatment with VEGF inhibitors did not significantly change FMD (from 4.7 ± 2.4 to 3.9 ± 1.9% after 8 weeks, p = 0.07, and to 5.1 ± 2.0% after 1 year; p = 0.93 vs. baseline, respectively). CONCLUSIONS: EF did not significantly differ between patients with neovascular AMD treated with intravitreal VEGF inhibition and patients with dry AMD. SN - 1423-0267 UR - https://www.unboundmedicine.com/medline/citation/28866675/SAVE_AMD:_Safety_of_VEGF_Inhibitors_in_Age_Related_Macular_Degeneration_ L2 - https://www.karger.com?DOI=10.1159/000478665 DB - PRIME DP - Unbound Medicine ER -